Is This Stock the Next Biotech Acquisition Target?

Tesaro, Inc. (NASDAQ: TSRO)shares are rallying this week on rumors it's an acquisition target. The company, which markets two cancer drugs, recently increased its sales guidance because of growing demand. Given that shares are trading at a steep discount to where they were last year, it could be the perfect time for a suitor to come knocking.

Here's what investors should know about this company and why it could be attractive to a buyer.